https://scholars.lib.ntu.edu.tw/handle/123456789/639592
標題: | Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study | 作者: | Kudo, Masatoshi Finn, Richard S ANN-LII CHENG Zhu, Andrew X Ducreux, Michel Galle, Peter R Sakamoto, Naoya Kato, Naoya Nakano, Michitaka Jia, Jing Vogel, Arndt |
關鍵字: | Albumin-bilirubin grade; Atezolizumab; Bevacizumab; Unresectable hepatocellular carcinoma | 公開日期: | 十月-2023 | 卷: | 12 | 期: | 5 | 來源出版物: | Liver cancer | 摘要: | Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/639592 | ISSN: | 2235-1795 | DOI: | 10.1159/000529996 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。